This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Winners & Losers: Cell Genesys

Cell Genesys (CEGE) soared Tuesday after announcing Monday post close that it signed Japanese drug maker Takeda Pharmaceutical as a global partner for GVAX Prostate, a prostate cancer vaccine in late-stage development. Takeda will pay Cell Genesys $50 million upfront, up to $270 in milestones tied to regulatory approvals and commercialization, and also royalties on future sales. The stock added 69 cents, or 29%, to $3.04.

Akamai (AKAM - Get Report) gained $2.67, or 9.5%, to $30.83 after the stock got a thumbs up from two Wall Street analysts.

An analyst at Piper Jaffray upgraded the stock to buy from neutral while a Citigroup analyst reiterated his buy rating on the belief that the company's business remains strong because of continued momentum for online video.

Then Progenics Pharmaceutical (PGNX - Get Report) and Wyeth (WYE) excelled after the companies said their partnered constipation drug Relistor was approved for sale in Canada. Relistor is an injection for constipation resulting from opiate pain medications in patients with advanced illness who have tried laxatives unsuccessfully.

Progenics shares traded up 16.5% to $7.61, and Wyeth traded up 1.7% to $42.48.

Shares of Palm (PALM) were up 43 cents, or 8.6%, to $5.43 after the company said late Monday that it sold one million devices of its latest smartphone Palm Centro since it went on sale September.

Also gaining, Buffalo Wild Wings (BWLD - Get Report), a Minneapolis restaurant chain, jumped 12.2% to $27.50 after Morgan Keegan bumped the stock's rating to outperform from market perform.

Shares of Kandi Technologies (KNDI - Get Report), a maker of all-terrain vehicles, go-karts and other vehicles in China, zoomed ahead 15.9% to $6.48. For the full year 2007, Kandi announced income of $5 million, or 31 cents a share, vs. $1.1 million, or 10 cents a share, in 2006. Revenue more than doubled to $34.7 million.
This article was written by a staff member of

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AKAM $70.23 0.00%
BWLD $193.58 0.00%
KNDI $5.73 0.00%
PGNX $5.90 0.00%
AAPL $110.38 0.00%


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs